Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

After back-to-back years of 20%-plus gains in 2023 and 2024, the S&P 500 is off to another strong start to 2025. However, the S&P 500's forward earnings multiple of 22 (as of Feb. 7) was also ...

in the EU and UK anticipated in calendar Q1 2025Strategic partnership with Cencora (formerly AmerisourceBergen) to support the planned commercial launches of LYTENAVA in UK and EU ISELIN ...

AmerisourceBergen’s move into the digital health area is part of a revamp of the business, which will be renamed Cencora later this year to reflect a change in business strategy, with ...

Outlook has teamed up with Cencora (formerly AmerisourceBergen) and its European partners to support commercialisation of Lytenava in the UK and selected EU countries, and has said it plans to ...

She is also Chair of the Corporate Social Responsibility Committee. Ornella is a member of the Board of Directors of Cencora (formerly known as AmerisourceBergen) and sits on the Board of the ...

AmerisourceBergen Corp is a pharmaceutical services company. It provides drug distribution and related healthcare services and solutions to pharmacy, physician, and manufacturer customers based in the ...

Over the past year, many Cencora, Inc. (NYSE:COR) insiders sold a significant stake in the company which may have piqued investors' interest. Knowing whether insiders are buying is usually more ...

Over the past year, many Cencora, Inc. (NYSE:COR) insiders sold a significant stake in the company which may have piqued investors' interest. Knowing whether insiders are buying is usually more ...

Nearly 200 medications, including several oncology treatments, are now available through the program.